Northern Trust Corp grew its holdings in Codexis, Inc. (NASDAQ:CDXS) by 28.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 453,656 shares of the biotechnology company’s stock after acquiring an additional 101,432 shares during the period. Northern Trust Corp owned about 0.94% of Codexis worth $2,473,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Nationwide Fund Advisors lifted its position in shares of Codexis by 15.7% in the second quarter. Nationwide Fund Advisors now owns 21,568 shares of the biotechnology company’s stock worth $118,000 after buying an additional 2,928 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Codexis by 7.1% in the second quarter. TIAA CREF Investment Management LLC now owns 109,557 shares of the biotechnology company’s stock worth $597,000 after buying an additional 7,263 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Codexis by 16.5% in the second quarter. Teachers Advisors LLC now owns 67,569 shares of the biotechnology company’s stock worth $368,000 after buying an additional 9,552 shares in the last quarter. White Pine Capital LLC purchased a new stake in shares of Codexis in the second quarter worth about $277,000. Finally, Baillie Gifford & Co. lifted its position in shares of Codexis by 23.3% in the second quarter. Baillie Gifford & Co. now owns 1,461,413 shares of the biotechnology company’s stock worth $7,965,000 after buying an additional 276,280 shares in the last quarter. Institutional investors own 65.71% of the company’s stock.

Shares of Codexis, Inc. (CDXS) opened at $6.15 on Tuesday. Codexis, Inc. has a 52 week low of $3.60 and a 52 week high of $7.95.

In other Codexis news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $5.78, for a total transaction of $6,126,800.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 9.80% of the company’s stock.

A number of equities research analysts recently commented on the company. Jefferies Group LLC boosted their target price on Codexis from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Friday, October 13th. HC Wainwright boosted their target price on Codexis from $8.00 to $8.50 and gave the stock a “buy” rating in a research report on Friday, October 13th. Zacks Investment Research upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. ValuEngine upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $7.50.

WARNING: “Codexis, Inc. (CDXS) Shares Bought by Northern Trust Corp” was published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/28/codexis-inc-cdxs-shares-bought-by-northern-trust-corp.html.

Codexis Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.